The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038).
 
Sherise C. Rogers
No Relationships to Disclose
 
Brian Hemendra Ramnaraign
No Relationships to Disclose
 
Kathryn Hitchcock
Research Funding - BioMimetix; Merck
Travel, Accommodations, Expenses - Merck
 
Steven J. Hughes
No Relationships to Disclose
 
Ji-Hyun Lee
No Relationships to Disclose
 
Z. Hugh Fan
No Relationships to Disclose
 
Carmen Joseph Allegra
No Relationships to Disclose
 
Jose Trevino
No Relationships to Disclose
 
Ahmad El-Far
No Relationships to Disclose
 
Anita Ahmed Turk
Honoraria - Exelixis
Research Funding - Lilly (Inst)
 
Karen Bullock Russell
No Relationships to Disclose
 
David L. DeRemer
Leadership - Hematology/Oncology Pharmacy Association
Honoraria - Bristol-Myers Squibb (I); Pfizer (I); Pharmacy Times; Pharmacy Times
 
Thomas J. George
Consulting or Advisory Role - Tempus
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst); Tesaro (Inst)